Grifols Initiates Clinical Investigation of New Treatment Protocol for Alzheimer's Disease

07-Jun-2010 - Spain

Grifols, SA announced at its annual meeting with investors and analysts, that it will initiate a new clinical investigation of Alzheimer's disease in January 2011with an anticipated enrollment of over 300 patients.

The new clinical investigation involves a combined treatment of therapeutic plasmapheresis and the administration of human albumin and intravenous immune globulin (IVIG) at different doses and frequencies. Human albumin and IVIG are two of the main therapeutic plasma proteins Grifols produces from donations of human blood plasma at dedicated donation centers acrossthe United States.

In conjunction with the announcement of the new clinical investigation, Grifols also announced that it has entered into an exclusive design and development agreement with U.S.-based Fenwal, Inc. for the production of a prototype plasmapheresis device specifically adapted for use in Grifols' Alzheimer's research. Fenwal is expected to deliver the first prototype devices at the end of this year. It is anticipated that the 2011 study will take place over the course of two years.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances